Fluoropharma Medical Inc. (FPMI)
OTC PINK OTC PINK Primary Summary
Fluoropharma Medical Inc. (FPMI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fluoropharma Medical Inc. ever had a stock split?
Fluoropharma Medical Inc. Profile
| Biotechnology Industry | Healthcare Sector | Edward L. Lyons Jr. CEO | OTC PINK Exchange | 343870101 CUSIP |
| US Country | 4 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
FluoroPharma Medical, Inc. is a pioneering biopharmaceutical company deeply engaged in the innovation, development, and commercialization of molecular imaging pharmaceuticals, primarily catering to cardiology needs in the United States. Founded in 2003 and based in Montclair, New Jersey, the company embarks on fulfilling the critical medical industry gap by providing advanced diagnostic solutions targeted at coronary artery disease (CAD) and related cardiac conditions. Through strategic license agreements with notable institutions such as Massachusetts General Hospital and Sinotau USA, along with clinical research agreements with entities like Pharmaceutical Product Development, LLC, and Cardiovascular Imaging Technologies, FluoroPharma is at the forefront of enhancing patient care in cardiology through molecular imaging technology.
Products and Services
- BFPET
An innovative imaging agent, BFPET is designed for use in stress-testing among patients with suspected or confirmed coronary artery disease (CAD). This agent has successfully completed a Phase I clinical trial, showcasing its potential to significantly improve the detection and management of CAD by providing critical information on heart function under stress conditions. BFPET aims at elevating the standards of CAD diagnosis, potentially leading to better patient outcomes through earlier and more accurate detection.
- CardioPET
Currently in a Phase IIa clinical trial, CardioPET is a sophisticated molecular imaging agent, intended for the assessment of myocardial blood flow and metabolism in patients with CAD. This product epitomizes the intersection of innovative pharmaceuticals and advanced imaging technology, offering a non-invasive approach to assessing heart diseases. The development of CardioPET underscores FluoroPharma's commitment to pioneering diagnostic solutions that assist in the early detection and effective management of cardiac conditions, thereby improving the quality of life for patients with coronary artery diseases.
